Eco Animal Health Group PLC
13 July 2026
13 July 2026
ECO Animal Health Group plc
("ECO" or the "Company")
Notice of Results
Analyst briefing and investor presentation
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it will issue its audited results for the year ended 31 March 2026 on 15 July 2026.
David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person briefing for equity research analysts at 09:00 BST on 15 July 2026. There will be a dial-in option for those analysts unable to attend in person.
For further information about the analyst presentation, please contact ecoanimalhealth@icrhealthcare.com.
In addition, David Hallas and Christopher Wilks will conduct a live online presentation of the results at 09:00 BST on 16 July 2026. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at its conclusion.
To register for the event, please click here.
A recording will be available shortly after the event on Equity Development's website here.
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer) |
020 8447 8899 |
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Jalini Kalaravy Samed Ethemi |
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden |
020 3100 2000 |
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
About ECO Animal Health
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
The Group's proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in June 2026.
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
View the Group's website or LinkedIn page for further information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.